Hallucinations pp 297-316 | Cite as

Psychoactive Substances

Chapter

Abstract

This chapter discusses some substances that are particularly likely to induce hallucinations. Many such drugs are available in nature and have long histories of use; more have emerged from laboratories either accidentally or as the result of purposeful research. Many more substances than these can elicit hallucinations, given the natural corporeal variations among individuals. Most substance-induced alterations consist of “partial hallucinations” in which an actual sensory stimulus is involved; the hallucinator tends to be aware of the difference between the hallucinogen-affected experiences of that stimulus and of a usual sensorium. Sometimes a complete loss of contextual meaning is evoked, in which the hallucinator experiences an essentially different environment (i.e., a scenic or panoramic hallucination), and either loses awareness of his sensory surroundings or becomes unable to recognize them as such. It can only be hoped that science’s endless curiosity will continue to press the societal restraints upon their use, and knowledge continue to accrue. The scientific process has tremendous resilience; those of us who would practice it need only to retain our faith and do our jobs. Further pursuit of such research may reveal that drug-induced hallucinatory phenomena offer a systematized route to observe not just how the brain processes hallucinations, but better clarify how our awareness of reality is consistently distorted.

Keywords

Placebo Fatigue Schizophrenia NMDA Alkaloid 

References

  1. Amanzio, M., Pollo, A., Maggi, G., Benedetti, F. (2001). Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain, 90, 205–215.PubMedCrossRefGoogle Scholar
  2. Arora, D. (1990). Mushrooms demystified. Second edition. Berkeley, CA: Ten Speed Press.Google Scholar
  3. Benedetti, F., Arduino, C., Costa, S., Vighetti, S., Tarenzi, L., Rainero, I., Asteggiano, G. (2006). Loss of expectation-related mechanisms in Alzheimer’s disease makes analgesic therapies less effective. Pain, 121, 133–144.PubMedCrossRefGoogle Scholar
  4. Capaldi, V.F. 2nd, Carr, R.B. (2010). Citalopram-induced hallucinations and delusions in a young adult. General Hospital Psychiatry, 32, 648.PubMedCrossRefGoogle Scholar
  5. Cunningham, B.L., McKinney, P. (1983). Patient acceptance of dissociative anesthetics. Plastic and Reconstructive Surgery, 72, 22–26.PubMedCrossRefGoogle Scholar
  6. De Smet, P.A.G.M., Bruhn, J.G. (2003). Ceremonial peyote use and its antiquity in the Southern United States. HerbalGram, 53, 30–33.Google Scholar
  7. District Officers from Kamerun (1888). Mitteilungen aus den Deutschen Schutzgebieten, Volume 1, p. 49.Google Scholar
  8. Doblin, R. (1991). Pahnke’s “Good Friday Experiment”: A long-term follow-up and methodological critique. Journal of Transpersonal Psychology, 23, Vol. 1.Google Scholar
  9. Estrada, Á. (1981). María Sabina: her life and chants. Santa Barbara, CA: Ross-Erikson.Google Scholar
  10. Fei, L., Tsien, J. (2009). Memory and the NMDA Receptors. New England Journal of Medicine, 361, 302–303.CrossRefGoogle Scholar
  11. Fernandez, J.W. (1982). Bwiti: an ethnography of the religious imagination in Africa. Princeton, NJ: Princeton University Press.Google Scholar
  12. Fontanilla, D., Johannessen, M., Hajipour, A., Cozzi, N., Jackson, M., Ruoho, A. (2009). The hallucinogen N,N-Dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, 323, 934–935.PubMedCrossRefGoogle Scholar
  13. Geyer, M.A., Vollenweider, F.X. (2008). Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences, 29, 445–453.PubMedCrossRefGoogle Scholar
  14. Ghansah, E., Kopsombut, P., Malleque, M.A., Brossi, A. (1993). Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission. Neuropharmacology, 32, 169–174.PubMedCrossRefGoogle Scholar
  15. Glick S.D., Maisonneuve I.S. (1998). Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences, 844, 214–26.PubMedCrossRefGoogle Scholar
  16. Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., Kovar, K.A. (2005). Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry, 38, 301–311.PubMedCrossRefGoogle Scholar
  17. Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O., Arning, C., Thelen, B., Spitzer, M., Kovar, K.A., Hermle, L., Büll, U., Sass, H. (1999). Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers A double-blind, placebo-controlled PET study with [18 F]FDG. Neuropsychopharmacology, 20, 565–581.PubMedCrossRefGoogle Scholar
  18. Griffiths, R., Richards, W., McCann, U. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268–283.PubMedCrossRefGoogle Scholar
  19. Guzmán, G., Allen, J.W., Gartz, J. (2000). A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. Annali di Museo Civico di Roverreto, 14, 189–280.Google Scholar
  20. Hoffer, A., Osmond, H. (1967). The hallucinogens. New York, NY: Academic Press.Google Scholar
  21. Hofmann, A. (1969). LSD ganz persönlich. Translated from the original German by J. Ott (1996). In Newsletter of the Multidisciplinary Association for Psychedelic Studies, Vol. 6, Nr. 3.Google Scholar
  22. Hofmann, A. (1980). LSD: My problem child. Translated by J. Ott. New York, NY: McGraw-Hill.Google Scholar
  23. Kelly, K. (1999). The little book of ketamine. Berkeley, CA: Ronin Publishing.Google Scholar
  24. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr., Charney, D.S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199–214.PubMedCrossRefGoogle Scholar
  25. Lotsof, H. (1985). US Patent 4,499,096, Rapid Method for Interrupting the Narcotic Addiction Syndrome.Google Scholar
  26. Lotsof, H. (1992). US Patent 5,152,994, Rapid Method for Interrupting or Attenuating Poly-Drug Dependency Syndromes.Google Scholar
  27. McKenna, T. (1992). The archaic revival: Speculations on psychedelic mushrooms, the Amazon, virtual reality, UFOs, evolution, shamanism, the rebirth of the goddess, and the end of history. New York, NY: HarperCollins.Google Scholar
  28. Naranjo, C.C. (1974). The healing journey. New York, NY: Pantheon Books.Google Scholar
  29. Pahnke, W.N. (1963). Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the Committee on Higher Degrees in History and Philosophy of Religion. Cambridge, MA: Harvard University.Google Scholar
  30. Patel, J., Pinals, D.A., Breier, A. (2008). Schizophrenia and other psychoses. In Psychiatry, third edition. Edited by Tasman, A., Kay, J., and Lieberman, J.A. Chichester: Wiley.Google Scholar
  31. Passie, T., Halpern, J.H., Stichtenoth, D.O., Emrich, H.M., Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14, 295–314.CrossRefGoogle Scholar
  32. Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., Barbanoj, M.J. (2006). Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology, 186, 93–98.PubMedCrossRefGoogle Scholar
  33. Sanford, J.H. (1972). Japan’s ‘laughing mushrooms’. Economic Botany, 26, 174–181.CrossRefGoogle Scholar
  34. Schultes, R.E., Hofmann, A. (1973). The botany and chemistry of hallucinogenic plants. Springfield, IL: Charles C. Thomas.Google Scholar
  35. Shimizu, S., Watanabe, K., Jibiki, I. (2010). Auditory hallucinations associated with clinical dosage of paroxetine: a case report. Psychiatry and Clinical Neurosciences, 64, 666–667.PubMedCrossRefGoogle Scholar
  36. Shulgin, A., Shulgin, A. (1991). Phenethylamines I have known and loved. Berkeley, CA: Transform Press.Google Scholar
  37. Shulgin, A., Shulgin, A. (1997). Tryptamines I have known and loved. Berkeley, CA: Transform Press.Google Scholar
  38. Trulson, M.E., Crisp, T., Henderson, L.J. (1983). Mescaline elicits behavioral effects in cats by an action at both serotonin and dopamine receptors. European Journal of Pharmacology, 96, 151–154.PubMedCrossRefGoogle Scholar
  39. Vollenweider, F.X., Geyer, M.A. (2001). A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin, 56, 495–507.PubMedCrossRefGoogle Scholar
  40. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., Maguire, P., Stadelmann, O., Angst, J. (1997a). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology, 16, 357–372.PubMedCrossRefGoogle Scholar
  41. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., Angst J. (1997b). Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18 F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology, 7, 9–24.PubMedCrossRefGoogle Scholar
  42. Wasson, G.W. (1980). The wondrous mushroom: Mycolatry in Mesoamerica. New York, NY: McGraw-Hill.Google Scholar
  43. Wasson, V.P., Wasson, G.W. (1957). Mushrooms, Russia, and history. New York, NY: Pantheon Books.Google Scholar
  44. Zinberg, N. (1986). Drug, set, and setting: The basis for controlled intoxicant use. New Haven, CT: Yale University Press.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Vicka Corey
    • 1
    • 2
  • John H. Halpern
    • 1
    • 2
  • Torsten Passie
    • 3
  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.The Laboratory for Integrative Psychiatry, Division of Alcohol and Drug AbuseMcLean HospitalBelmontUSA
  3. 3.Department for Psychiatry, Social Psychiatry, and PsychotherapyHannover Medical SchoolHannoverGermany

Personalised recommendations